LLY

1,076.96

+0.06%↑

JNJ

207.49

-0.14%↓

ABBV

230.16

+0.01%↑

UNH

331.59

+1.17%↑

AZN

92.89

+0.42%↑

LLY

1,076.96

+0.06%↑

JNJ

207.49

-0.14%↓

ABBV

230.16

+0.01%↑

UNH

331.59

+1.17%↑

AZN

92.89

+0.42%↑

LLY

1,076.96

+0.06%↑

JNJ

207.49

-0.14%↓

ABBV

230.16

+0.01%↑

UNH

331.59

+1.17%↑

AZN

92.89

+0.42%↑

LLY

1,076.96

+0.06%↑

JNJ

207.49

-0.14%↓

ABBV

230.16

+0.01%↑

UNH

331.59

+1.17%↑

AZN

92.89

+0.42%↑

LLY

1,076.96

+0.06%↑

JNJ

207.49

-0.14%↓

ABBV

230.16

+0.01%↑

UNH

331.59

+1.17%↑

AZN

92.89

+0.42%↑

Search

Celldex Therapeutics Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

26.39 -1.38

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

25.18

Max

26.51

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-10M

-67M

Pelnas, tenkantis vienai akcijai

-1.01

Pelno marža

-7,753.425

Darbuotojai

186

EBITDA

-9.8M

-73M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+104.99% upside

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

307M

1.8B

Ankstesnė atidarymo kaina

27.77

Ankstesnė uždarymo kaina

26.39

Naujienos nuotaikos

By Acuity

50%

50%

157 / 374 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Weak Bullish Evidence

Celldex Therapeutics Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-12-24 21:41; UTC

Įsigijimai, susijungimai, perėmimai

Nvidia to Buy Chip-Designer Groq for $20 Billion, CNBC Reports

2025-12-26 20:22; UTC

Rinkos pokalbiai

Oil Loses Ground On Russia-Ukraine Peace Efforts -- Market Talk

2025-12-26 20:13; UTC

Rinkos pokalbiai

U.S. Natural Gas Gains on Colder Weather Outlook -- Market Talk

2025-12-26 19:24; UTC

Įsigijimai, susijungimai, perėmimai

Nvidia's Groq Deal Is an Instagram Moment -- With 1 Big Risk -- Barrons.com

2025-12-26 17:45; UTC

Rinkos pokalbiai

U.S. Diesel Down on Lower Crude Prices, Freight-Sector Lull -- Market Talk

2025-12-26 15:52; UTC

Rinkos pokalbiai

Oil Futures Turn Lower After Steady Start -- Market Talk

2025-12-26 14:58; UTC

Rinkos pokalbiai

Silver, Gold Reach New Highs Amid Geopolitical Tension -- Market Talk

2025-12-26 14:41; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures Look to End Week Higher -- Market Talk

2025-12-26 14:28; UTC

Rinkos pokalbiai

Dollar Indexes Flat as Yen Rally Wanes -- Market Talk

2025-12-26 13:47; UTC

Rinkos pokalbiai

Oil Futures Steady in Thin Holiday Trade -- Market Talk

2025-12-26 07:22; UTC

Rinkos pokalbiai

Comex Gold Futures' Strong Bullish Momentum in Play, Chart Shows -- Market Talk

2025-12-26 05:03; UTC

Rinkos pokalbiai

Malaysian Ringgit Likely to Face Pressure From Dollar Strength in 1Q -- Market Talk

2025-12-26 03:38; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2025-12-26 03:38; UTC

Rinkos pokalbiai

Korean Won Strengthens, Supported by Verbal Interventions -- Market Talk

2025-12-26 02:44; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-12-26 02:44; UTC

Rinkos pokalbiai

Singapore Dollar Weakens Slightly on Likely Position Adjustments -- Market Talk

2025-12-26 01:39; UTC

Rinkos pokalbiai

China's Central Bank Signals Possibility of Easing Policy in Coming Months -- Market Talk

2025-12-26 01:14; UTC

Rinkos pokalbiai

Oil Edges Higher Amid Geopolitical Tensions -- Market Talk

2025-12-26 00:34; UTC

Rinkos pokalbiai

Yen Mostly Weakens Amid Risk-on Sentiment -- Market Talk

2025-12-26 00:15; UTC

Rinkos pokalbiai

Nikkei Gains 0.6%, Led by Tech, Videogame Stocks -- Market Talk

2025-12-25 23:42; UTC

Rinkos pokalbiai

Nikkei May Trade in Range; Yen in Focus -- Market Talk

2025-12-25 23:40; UTC

Rinkos pokalbiai

Gold Edges Higher Amid Geopolitical Risks -- Market Talk

2025-12-25 00:20; UTC

Įsigijimai, susijungimai, perėmimai

Nike Climb Boosts Dow, S&P 500 -- 2nd Update

2025-12-24 22:22; UTC

Įsigijimai, susijungimai, perėmimai

Nvidia, Groq Strike AI Tech Licensing Deal -- Barrons.com

2025-12-24 21:26; UTC

Įsigijimai, susijungimai, perėmimai

Nvidia to Buy Chip-Designer Groq for $20B, CNBC Reports

2025-12-24 19:35; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-12-24 19:35; UTC

Rinkos pokalbiai

Treasury Yields Decline Ahead of Christmas -- Market Talk

2025-12-24 19:09; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Global Equities Roundup: Market Talk

2025-12-24 19:09; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

ServiceNow's Armis Acquisition Shouldn't Fuel Fears That Seat-Based Model Threatened -- Market Talk

2025-12-24 19:06; UTC

Rinkos pokalbiai

Oil Futures Little Changed in Light Pre-Holiday Trade -- Market Talk

Akcijų palyginimas

Kainos pokytis

Celldex Therapeutics Inc Prognozė

Kainos tikslas

By TipRanks

104.99% į viršų

12 mėnesių prognozė

Vidutinis 55 USD  104.99%

Aukščiausias 90 USD

Žemiausias 24 USD

Remiantis 10 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Celldex Therapeutics Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

10 ratings

9

Pirkti

0

Laikyti

1

Parduoti

Techninis įvertinimas

By Trading Central

18.91 / 20.63Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Weak Bullish Evidence

Vidutinės trukmės periodas

Bullish Evidence

Ilgalaikis periodas

Bearish Evidence

Rinkos nuotaikos

By Acuity

157 / 374 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Neutral

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Vidutinis

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Celldex Therapeutics Inc

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.
help-icon Live chat